Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.38 |
| ▸ | JAK1 | P23458 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566439 | 0.91 | JAK1 (0.43) | SCN9ASCN5AKCNH2JAK1DRD2 | |
| SCHEMBL565493 | 0.90 | SCN9A (0.36) | SCN9ASCN5AKCNH2JAK1JAK2 | |
| SCHEMBL565492 | 0.90 | SCN9A (0.36) | SCN9ASCN5AKCNH2JAK1JAK2 | |
| SCHEMBL567232 | 0.90 | SCN9A (0.37) | SCN9ASCN5AKCNH2JAK1JAK2 | |
| SCHEMBL16477544 | 0.89 | SCN9A (0.39) | SCN9ASCN5AKCNH2JAK1DRD2 | |
| SCHEMBL10099181 | 0.88 | JAK1 (0.42) | SCN9ASCN5AKCNH2JAK1JAK2 | |
| SCHEMBL14697506 | 0.88 | JAK1 (0.43) | SCN9ASCN5AKCNH2JAK1JAK2 | |
| SCHEMBL14697123 | 0.88 | SCN9A (0.38) | SCN9ASCN5AKCNH2JAK1JAK2 | |
| SCHEMBL14697175 | 0.88 | SCN9A (0.38) | SCN9ASCN5AKCNH2JAK1JAK2 | |
| SCHEMBL10099169 | 0.87 | EGFR (0.39) | SCN9ASCN5AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556187-B2 | Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9556187-B2 | Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-3112370-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2017-01-04 | — | — | EP | disclosed |
| EP-3112370-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-9216999-B2 | Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| US-9216999-B2 | Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| US-20140200344-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-07-17 | — | — | US | disclosed |
| EP-2742049-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013024895-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024895-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-02-21 | — | — | WO | disclosed |
| EP-2420502-A1 | FUSED PYRROLOPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | JAK2, JAK1, JAK3 | SCN9A 3095/4885SCN5A 1019/4885KCNH2 1026/4885 |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | JAK2, JAK1, JAK3 | SCN9A 4044/4885SCN5A 4421/4885KCNH2 3229/4885 |
| US-20140200344-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | JAK2, JAK1, JAK3 | SCN9A 3598/4885SCN5A 4034/4885KCNH2 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.